An Improved Outlook for Patients with Acute Leukemia over the Last 14 Years: A Perspective from a University Hospital.
- Author:
Kyoo Hyung LEE
1
;
Seong Jun CHOI
;
Jung Hee LEE
;
Chang Hoon LEE
;
Miee SEOL
;
Young Shin LEE
;
Jung Shin LEE
;
Woo Kun KIM
;
Je Hwan LEE
Author Information
1. Sections of Hematology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea. khlee2@amc.seoul.kr
- Publication Type:Original Article
- Keywords:
Acute leukemia;
Patient survival
- MeSH:
Adult;
Cell Transplantation;
Chungcheongnam-do;
Cohort Studies;
Cytarabine;
Demography;
Diagnosis;
Drug Therapy;
Drug Therapy, Combination;
Hospital Records;
Humans;
Idarubicin;
Leukemia*;
Leukemia, Myeloid, Acute;
Leukemia, Promyelocytic, Acute;
Lost to Follow-Up;
Medical Records;
Multivariate Analysis;
Precursor Cell Lymphoblastic Leukemia-Lymphoma;
Retrospective Studies;
Seoul;
Survival Rate;
Transplants
- From:Korean Journal of Hematology
2004;39(3):127-133
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: To see whether there has been improvement in the survival of patients with acute leukemia over the last 14 years, a retrospective analysis was performed. METHODS: Clinical and laboratory data were obtained form the medical records. Patient survival data was obtained from the hospital records, national cancer registry or by direct phone contacts. RESULTS: Between June, 1989 and August 2002, 714 adult patients were diagnosed with acute leukemia at Asan Medical Center in Seoul. Fourteen patients were lost to follow-up within 100 days of the diagnosis and excluded. There were 535 patients with acute myelogenous leukemia (AML) and 165 with acute lymphoblastic leukemia (ALL). There were 65 patients with acute promyelocytic leukemia (APL) among 535 patients with AML. Patients with non-APL AML and ALL were divided into 3 cohorts according to the year of the diagnosis: cohort I, 1989~1994; cohort II, 1995~1998; cohort III, 1999~2002. Patients with APL were also divided into 3 cohorts: cohort I, pre-all-transretinoic acid (ATRA) period (1989~1994. 2); cohort II, ATRA with or without chemotherapy (1994. 3~2000. 8); and cohort III, ATRA plus idarubicin (2000. 9~2002). Univariate analysis showed significant improvement in patient survival in non-APL AML (4-year projected survival rates of 10%, 19%, and 33% for cohorts I, II, and III, respectively, P=0.0000), in ALL (27%, 28%, and 52%, P=0.03), and in APL (36%, 56%, and 80%, P=0.04). Multivariate analysis showed that the year of diagnosis was a significant independent variable for patient survival in non-APL AML and ALL. CONCLUSION: Our study showed significant survival improvement in acute leukemia over the last 14 years. This improvement is not likely due to change in patient demographics. Rather, it is likely that introduction of newer methods of treatment of acute leukemia, such as multi-cycle combination chemotherapy for ALL, high dose cytarabine consolidation for AML, ATRA for APL, and wider application of allogeneic hematopoietic cell transplantation, has resulted in a better patient survival.
